Jazz Pharmaceuticals (JAZZ) Short-term Investments (2011 - 2017)
Jazz Pharmaceuticals' (JAZZ) quarterly Short-term Investments came in at $200.0 million in Q3 2017, up 236.6% year-on-year from $59.4 million in Q3 2016, and up 150.0% quarter-over-quarter from $80.0 million in Q2 2017.
Jazz Pharmaceuticals (JAZZ) Short-term Investments (2011 - 2017) Analysis & Trends
Jazz Pharmaceuticals' Short-term Investments history runs 4 years deep, the most recent figure standing at $200.0 million for Q3 2017.
- On a quarterly basis, Short-term Investments rose 236.6% year-over-year to $200.0 million in Q3 2017; TTM through Sep 2017 was $200.0 million, a 236.6% increase from a year earlier, with the FY2016 full-year figure at $60.0 million, changed N/A from the prior year.
- Short-term Investments rose to $200.0 million in Q3 2017 per JAZZ's latest filing, from $80.0 million in the prior quarter.
- Across five years, Short-term Investments topped out at $200.0 million in Q3 2017 and bottomed at $764000.0 in Q1 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Jazz Pharmaceuticals | 15.78 Bn | 13.93 Bn | 934.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2017 | 200.00 Mn |
| Jun 30, 2017 | 80.00 Mn |
| Mar 31, 2017 | 60.00 Mn |
| Dec 31, 2016 | 60.00 Mn |
| Sep 30, 2016 | 59.42 Mn |
| Jun 30, 2016 | 48.41 Mn |
| Mar 31, 2016 | 764,000.00 |
| Mar 31, 2012 | 73.56 Mn |
| Dec 31, 2011 | 75.82 Mn |
| Sep 30, 2011 | 12.13 Mn |